Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor enzyme response type recombinant pyroptosis protein drug delivery system and anti-tumor purpose thereof

A protein and fusion protein technology, applied in the field of biomedicine, can solve problems such as difficulty in ensuring the efficiency of pyroptosis into cells

Active Publication Date: 2021-03-05
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, there are still some insurmountable difficulties in the study of pyroptosis in tumor cells
The N domain of pyroptin must be in the cell to function, and it is difficult to ensure the efficiency of pyroptosis in the existing technology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor enzyme response type recombinant pyroptosis protein drug delivery system and anti-tumor purpose thereof
  • Tumor enzyme response type recombinant pyroptosis protein drug delivery system and anti-tumor purpose thereof
  • Tumor enzyme response type recombinant pyroptosis protein drug delivery system and anti-tumor purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0181] Example 1: Purification results of FPLC

[0182] Primin (GSDMA3, GSDMA3-PTN and GSDMA3-TAT-PTN), which was preliminaryly purified by nickel column, and Hitrap Desalting ( figure 1 A-C) and gel exclusion layers (Superdex 75) (SUPERDEX 75) figure 1 D-f) was purified. The peak shape and peak position of three proteins are basically consistent, which is preliminarily indicated that the protein transformed by genetic engineering has not affected its structure and function.

Embodiment 2

[0183] Example 2: Purification and identification of fusion proteins

[0184] Samples of the top three absorption peaks of Superdex 75 were verified by SDS-PAGE electrophoresis. figure 2 Indicated. Lanes 1-9 are proteins of three absorption peaks of GSDMA3-TAT-PTN, GSDMA3-PTN, and GSDMA3, respectively. The strips of GSDMA3 are in line with a theoretical molecular weight of approximately 55kda (lane 7); GSDMA3-PTN strip (lane 4) Basic and GSDMA3 strips are basically at the same level, indicating that the molecular weight of both is close and theoretical; recombinant protein GSDMA3 -Tat-PTN strip (lane 1) has a significant movement; while other lanes have a conveyor, which indicates that the protein purity of the first absorption peak is better, while the other two absorption peaks have a large number of miscellaneous proteins. So subsequent experiments are used by the first absorption peak.

Embodiment 3

[0185] Example 3: WB detection of cell LeGumain expression level

[0186]The Legumain expression levels of RAW 264.7 and 4T1 cells induced into M2 macrophages were detected using Western blot. Such as image 3 As shown, LeGumain is highly expressed in tumor-related macrophages, which in vitro cultured 4T1 cells in vitro showed low expression of LeGumain enzyme.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a tumor enzyme response type recombinant pyroptosis protein drug delivery system and an anti-tumor purpose thereof. Specifically, the invention provides fusion protein which hasthe structure, which is disclosed by Z0-Z1-Z2-Z3-Z4 (formula I), from the N terminal to the C terminal,wherein Z0 is an optional tag element, Z1 is an N structural domain element of pyroptosis protein, Z2 is a cell-penetrating peptide sequence element, Z3 is a peptide sequence element which can be specifically segmented by specific expression protease in a tumor microenvironment, Z4 is a C structural domain element of the pyroptosis protein, and "-" shows a peptide bond for connecting the above elements. In the fusion protein, the Z4 element can be specifically combined with the Z1 element toinhibit the activity of the Z1 element. The fusion protection of the invention shows good anti-tumor activity in in vitro and vivo experiments.

Description

Technical field [0001] The present invention belongs to the field of biomedicine, and more particularly, the present invention relates to a tumor enzyme response type recombinant coke protein-related drug system and its anti-tumor use. Background technique [0002] Anovial protein is a class of Gasdermin Protein Family, which is capable of mediating cell-focused, with 45% sequence homology, including GSDMA (1-3), GSDMB, GSDMC (1-4), GSDMD, DFNA5 (GSDME), DFNB59 (GSDMF). [0003] In addition to DFNB59, other coke proteins have similar structures: including the two domains of N-Domain and C-domains and connectors connecting these two domains. Under normal circumstances, the two domains are closely integrated in self-suppression. [0004] Once Linker is cut, the C domain is destroyed to the suppression of the N domain to release the active N domain. The active N-domain and phosphatidyl inner alcohol (PI) or phosphatidylsenine (PS) of the cell membrane, or a cardiospholipin directly ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/70C12N1/21A61K38/17A61K47/64A61P35/00C12R1/19
CPCC07K14/47C12N15/70A61P35/00C07K2319/10C07K2319/50C07K2319/21A61K38/00A61K38/17A61K47/64C07K19/00C12N15/62A61K48/00C12R2001/19C12N1/205
Inventor 黄永焯黄晶晶陈应之
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com